Quick Answer
INTEGRATED BIOPHARMA INC reported Total Revenue of $43.71 million for fiscal year 2018.
INTEGRATED BIOPHARMA INC Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2018 | $43.71M | -6.9% |
| 2017 | $46.95M | +11.2% |
| 2016 | $42.21M | +12.6% |
| 2015 | $37.49M | +11.3% |
| 2014 | $33.68M | +0.2% |
| 2013 | $33.62M | -8.1% |
| 2012 | $36.60M | -10.0% |
| 2011 | $40.66M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2018 | $10.30M | +5.5% | -2.6% |
| March 31, 2018 | $10.57M | -0.7% | -2.1% |
| December 31, 2017 | $10.80M | -12.7% | +10.5% |
| September 30, 2017 | $9.77M | -23.0% | -8.3% |
| March 31, 2017 | $10.65M | -2.9% | -13.9% |
| December 31, 2016 | $12.37M | +18.8% | -2.4% |
| September 30, 2016 | $12.68M | +34.3% | +15.6% |
| March 31, 2016 | $10.97M | +13.4% | +5.4% |
- INTEGRATED BIOPHARMA INC showed a decrease of -6.9% in Total Revenue compared to the prior fiscal year.
- Over the 2011–2018 period, INTEGRATED BIOPHARMA INC’s total revenue has grown by 7.5% (from $40.66 million to $43.71 million).
- The most recent figure is from INTEGRATED BIOPHARMA INC’s fiscal year 2018 report (Form 10-K), filed with the SEC on September 12, 2018.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: